A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib

Olivia M. Lucero, Sarah Fitzmaurice, Curtis Thompson, Justin Leitenberger

Research output: Contribution to journalLetterpeer-review

1 Scopus citations

Abstract

Vismodegib is a small molecule inhibitor of the Hedgehog signaling pathway that has shown efficacy in the control of locally advanced or metastatic basal cell carcinoma, although proof of its effectiveness in the elimination of aggressive tumors is lacking. We report a case and provide complete histological evidence of a 69-year-old gentleman who presented with a recurrent, infiltrative, and sclerosing (morpheiform) basal cell carcinoma on his left upper lip that was entirely eradicated with a three-month course of vismodegib 150 mg daily. Complete histologic clearance of a tumor in a recurrent, infiltrative, and sclerosing basal cell carcinoma with vismodegib is uncommon.

Original languageEnglish (US)
Article number11
JournalDermatology Online Journal
Volume24
Issue number2
StatePublished - 2018

Keywords

  • Basal cell carcinoma
  • Hedgehog pathway
  • Vismodegib

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib'. Together they form a unique fingerprint.

Cite this